V
Vizgen
The first high multiplexing, high resolution in-situ platform to combine single-cell and spatial genomics
About Vizgen
Vizgen is a biotechnology startup that operates in the field of spatial genomics. The company's flagship product is MERSCOPE, a high-resolution imaging platform that integrates single-cell and spatial multiomics analyses. This technology allows researchers to study biological samples at a cellular and subcellular level, providing a detailed understanding of the spatial organization of tissues and cells.
Read full description
The company's technology is based on MERFISH chemistry, a method that enables high-quality, high-sensitivity spatial data collection. This technology is particularly useful in the field of immuno-oncology, where it can help researchers understand tumor and immune behavior across different types of human cancers.
Vizgen also offers a Gene Panel Design Portal, a user-friendly web-based application that guides researchers in building custom gene panels to run on the MERSCOPE platform. Additionally, the company provides a tool called VPT for cell segmentation, which draws cell boundaries and generates single-cell output by combining the results with MERFISH data.
Vizgen's business model revolves around selling its MERSCOPE platform and related services to research institutions and laboratories. The company generates revenue through the sale of its hardware platform, as well as through the provision of related services such as custom gene panel design and cell segmentation tools.
At a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Cambridge, United States
- Employees
- 158
- Open positions
- 3
- Dealroom signal
- 91.6/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Vizgen.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES EOther financing | Jan 2026 | $48M | $426M | ARCH Venture Partners · M Ventures · Northpond Ventures | ↗ |
| SERIES COther financing | Jun 2022 | $85M | $341M | Sofina · David R. Walt · Tao Capital Partners · Novalis Lifesciences | ↗ |
Growth signals
Latest recorded traffic for Vizgen is 28K monthly website visits, up 55.6% over the last three months. Vizgen's team grew 21.5% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
ARCH Venture Partners
Northpond Ventures
Novalis Lifesciences
David R. Walt- PIPura Vida Investments
Tao Capital Partners
Series B and later3 investors entered at this stage
Sofina- BSBlue Water Life Science
M Ventures
Other known investors1 additional known investor
Harvard University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Vizgen on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Vizgen’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.